Premium
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology
Author(s) -
Bezin Julien,
Duong Mai,
Lassalle Régis,
Droz Cécile,
Pariente Antoine,
Blin Patrick,
Moore Nicholas
Publication year - 2017
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.4233
Subject(s) - representativeness heuristic , medicine , database , pharmacoepidemiology , diagnosis code , health care , population , medical diagnosis , national database , family medicine , medical emergency , pediatrics , environmental health , computer science , statistics , nursing , economic growth , mathematics , pathology , medical prescription , economics
The French health care system is based on universal coverage by one of several health care insurance plans. The SNIIRAM database merges anonymous information of reimbursed claims from all these plans, linked to the national hospital‐discharge summaries database system (PMSI) and the national death registry. It now covers 98.8% of the French population, over 66 million persons, from birth (or immigration) to death (or emigration), making it possibly the world's largest continuous homogeneous claims database. The database includes demographic data; health care encounters such as physician or paramedical visits, medicines, medical devices, and lab tests (without results); chronic medical conditions (ICD10 codes); hospitalisations with ICD10 codes for primary, linked and associated diagnoses, date and duration, procedures, diagnostic‐related groups, and cost coding; date but currently not cause of death. The power of the database is correlatively great, and its representativeness is near perfect, since it essentially includes the whole country's population. The main difficulty in using the database, beyond its sheer size and complexity, is the administrative process necessary to access it. Recent legislative advances are making this easier. EGB ( Echantillon Généraliste de Bénéficiaires ) is the 1/97th random permanent representative sample of SNIIRAM, with planned 20‐year longitudinal data (10 years at this time). Access time is 1 to 3 months, but its power is less (780 000 subjects). This is enough to study common issues with older drugs but may be limited for new products or rare events.